Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Leistungen

The Purified Mtb cytochrome report will describe the methodology and confirmation of the purified cytochrome bc1, bc1:aa3, and bd

Continuous enzymatic assay and screening report

The continuous enzymatic assay and screening report will describe the assay, conditions and characterisation methodology of the continuous enzymatic assay for testing Mtr inhibitors and the application in the High Throughput Screening campaign.

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular MDRMtb strains in human cells

Website RespiriTB online

The website developed for communication of all RespiriTB activities will be active and online.

Veröffentlichungen

Host‐directed therapy to combat mycobacterial infections*

Autoren: Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Veröffentlicht in: Immunological Reviews, Ausgabe 301/1, 2021, Seite(n) 62-83, ISSN 0105-2896
Herausgeber: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951

Leistungen

Veröffentlichungen

Diese Seite teilen

Herunterladen